| SEC Form 4 | |
|------------|--|
| FORM 4 | |

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| | 3235-0287 |
|----------------------|--|
| Estimated average bu | rden |
| nours per response: | 0.5 |
| | DMB Number: Estimated average bu nours per response: |

| Check this box if no longer subject to Section 16. Form 4 or Form 5 | RSHIP |
|--|-------|
|--|-------|

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | of Section So(n) of the investment Company Act of 1940 | | | | | | |
|---|------------------------|-----------------|--|--|-----------------------------------|-----------------------|--|--|--|
| 1. Name and Address of Reporting Person [*] Evans John M. | | on [*] | 2. Issuer Name and Ticker or Trading Symbol Beam Therapeutics Inc. [BEAM] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
| | | | | X | Director | 10% Owner | | | |
| (Last) | Last) (First) (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) | x | Officer (give title below) | Other (specify below) | | | |
| C/O BEAM THERAPEUTICS INC. | | () | 04/21/2021 | CEO | | | | | |
| 26 LANDSDOV | VNE STREET | | | | | | | | |
| (Street) | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indiv Line) | vidual or Joint/Group Filing | (Check Applicable | | | |
| CAMBRIDGE | MA | 02139 | | X | Form filed by One Repo | orting Person | | | |
| | | | | | Form filed by More than Person | One Reporting | | | |
| (City) | (State) | (Zip) | | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| | | | | , | • | , | | | | |
|---------------------------------|--|---|---|---|--------|---------------|------------------------|---|---|--|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | | | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
| | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 04/21/2021 | | S ⁽¹⁾ | | 1,463 | D | \$67.9 ⁽²⁾ | 1,038,966 | D | |
| Common Stock | 04/21/2021 | | S ⁽¹⁾ | | 5,079 | D | \$69.02 ⁽³⁾ | 1,033,887 | D | |
| Common Stock | 04/21/2021 | | S ⁽¹⁾ | | 5,595 | D | \$70.23 ⁽⁴⁾ | 1,028,292 | D | |
| Common Stock | 04/21/2021 | | S ⁽¹⁾ | | 9,869 | D | \$71.38(5) | 1,018,423 | D | |
| Common Stock | 04/21/2021 | | S ⁽¹⁾ | | 2,994 | D | \$71.79 ⁽⁶⁾ | 1,015,429 | D | |
| Common Stock | 04/23/2021 | | М | | 6,000 | A | \$1.03 | 1,021,429 | D | |
| Common Stock | | | | | | | | 223,000 | I | By John M. Evans, III 2018 Irrevocable Trust |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of Deri Seci Acq (A) (Disp of (E (Inst | erivative (Month/Day/Year) ecurities cquired isposed | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
|---|---|--|---|------------------------------|---|--|---|---------------------|--|-----------------|---|--|--|--|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (Right to Buy) | \$1.03 | 04/23/2021 | | М | | | 6,000 | (7) | 07/13/2028 | Common Stock | 6,000 | \$0.00 | 396,345 | D | | | |

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. These shares were sold in multiple transactions ranging from \$67.67 to \$68.00 inclusive.

3. These shares were sold in multiple transactions ranging from \$68.67 to \$69.55 inclusive.

4. These shares were sold in multiple transactions ranging from \$69.68 to \$70.68 inclusive.

5. These shares were sold in multiple transactions ranging from \$70.68 to \$71.66 inclusive.

6. These shares were sold in multiple transactions ranging from \$71.68 to \$71.92 inclusive.

7. The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested.

Remarks:



04/23/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.